Literature DB >> 33816607

MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients.

Lin-Lin Tian1,2, Bin Qian3, Xiao-Hui Jiang4, Yu-Shan Liu5, Tong Chen6, Cheng-You Jia7, Ya-Li Zhou2, Ji-Bin Liu4, Yu-Shui Ma7, Da Fu7, Sen-Tai Ding1.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) have been demonstrated to exhibit important regulatory roles in multiple malignancies, including hepatocellular carcinoma (HCC). hsa-miR-497-5p was reported to involve in cancer progression and poor prognosis in many kinds of tumors. However, the expression and its clinical significance of hsa-miR-497-5p in HCC remain unclear.
METHODS: In the present study, we investigated the expression of hsa-miR-497-5p in HCC and analyzed the correction of clinical features with prognosis. The expression levels of hsa-miR-497-5p and potential target genes were analyzed in HCC and adjacent noncancerous tissues using The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to analyze hsa-miR-497-5p levels in 328 HCC tissues and 30 paired adjacent noncancer tissues. Overall survival (OS) and progression-free survival (PFS) of patients with HCC were assessed using the Kaplan-Meier method and the log-rank test.
RESULTS: The hsa-miR-497-5p expression levels were decreased, and its target genes ACTG1, CSNK1D, PPP1CC, and BIRC5 were upregulated in HCC tissues compared with normal tissues. Lower levels of hsa-miR-497-5p expression and higher levels of the four target genes were significantly associated with higher tumor diameter. Moreover, patients with lower hsa-miR-497-5p expression and higher target genes levels had shorter OS.
CONCLUSION: The expression levels of hsa-miR-497-5p may play an important regulatory role in HCC and are closely correlated with HCC progression and poor prognosis in patients. The hsa-miR-497-5p may be a specific therapeutic target for the treatment of HCC.
Copyright © 2021 Lin-Lin Tian et al.

Entities:  

Year:  2021        PMID: 33816607      PMCID: PMC7987441          DOI: 10.1155/2021/6670390

Source DB:  PubMed          Journal:  Int J Genomics        ISSN: 2314-436X            Impact factor:   2.326


  99 in total

1.  S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.

Authors:  Jiao-Yang Li; Ta Xiao; Hong-Mei Yi; Hong Yi; Juan Feng; Jin-Feng Zhu; Wei Huang; Shan-Shan Lu; Yan-Hong Zhou; Xin-Hui Li; Zhi-Qiang Xiao
Journal:  Cancer Lett       Date:  2018-12-21       Impact factor: 8.679

2.  p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.

Authors:  Beilei Zhang; Xinan Wang; Jiacong Deng; Haifeng Zheng; Wei Liu; Si Chen; Jie Tian; Fu Wang
Journal:  Cancer Lett       Date:  2019-06-01       Impact factor: 8.679

Review 3.  Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches.

Authors:  Daniela Rodrigues; Terezinha Souza; Danyel G J Jennen; Lieve Lemmens; Jos C S Kleinjans; Theo M de Kok
Journal:  Cancer Treat Rev       Date:  2019-06-27       Impact factor: 12.111

4.  Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues.

Authors:  Juan P Unfried; Guillermo Serrano; Beatriz Suárez; Paloma Sangro; Valeria Ferretti; Celia Prior; Loreto Boix; Jordi Bruix; Bruno Sangro; Víctor Segura; Puri Fortes
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

Review 5.  Peptides that immunoactivate the tumor microenvironment.

Authors:  Natsuki Furukawa; Aleksander S Popel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-01       Impact factor: 10.680

6.  Hypomethylation Causes MIR21 Overexpression in Tumors.

Authors:  Jun Lu; Ting Tan; Ling Zhu; Huiyue Dong; Ronghua Xian
Journal:  Mol Ther Oncolytics       Date:  2020-05-26       Impact factor: 7.200

7.  LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.

Authors:  Hua Liu; Haoyu Deng; Yajie Zhao; Can Li; Yu Liang
Journal:  J Exp Clin Cancer Res       Date:  2018-11-21

8.  Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.

Authors:  Dean A Fergusson; Neil L Wesch; Garvin J Leung; Jenna L MacNeil; Isidora Conic; Justin Presseau; Kelly D Cobey; Jean-Simon Diallo; Rebecca Auer; Jonathan Kimmelman; Natasha Kekre; Nader El-Sayes; Ramya Krishnan; Brian A Keller; Carolina Ilkow; Manoj M Lalu
Journal:  Mol Ther Oncolytics       Date:  2019-05-21       Impact factor: 7.200

9.  Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.

Authors:  Yusha Xiao; Rahmathullah Mohamed Najeeb; Dong Ma; Kang Yang; Qiu Zhong; Quanyan Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-11-08

10.  lncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4.

Authors:  Yixi Zhang; Zebin Zhu; Shanzhou Huang; Qiang Zhao; Changjun Huang; Yunhua Tang; Chengjun Sun; Zhiheng Zhang; Linhe Wang; Huadi Chen; Maogen Chen; Weiqiang Ju; Xiaoshun He
Journal:  Cancer Cell Int       Date:  2019-07-29       Impact factor: 5.722

View more
  3 in total

1.  Actin gamma 1 is a critical regulator of pancreatic ductal adenocarcinoma.

Authors:  Yichen Tang; Xuehui Peng; Xiaobing Huang; Jing Li
Journal:  Saudi J Gastroenterol       Date:  2022 May-Jun       Impact factor: 3.214

2.  Prognostic microRNAs associated with phosphoserine aminotransferase 1 in gastric cancer as markers of bone metastasis.

Authors:  Jingwei Ma; Meng Zhu; Xiaofeng Ye; Bo Wu; Tao Wang; Muyuan Ma; Tao Li; Ning Zhang
Journal:  Front Genet       Date:  2022-08-19       Impact factor: 4.772

3.  A miR-212-3p/SLC6A1 Regulatory Sub-Network for the Prognosis of Hepatocellular Carcinoma.

Authors:  Dan-Dan Zhang; Wen-Er Wang; Yu-Shui Ma; Yi Shi; Jie Yin; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Da Fu; Wen-Jie Zhang
Journal:  Cancer Manag Res       Date:  2021-06-28       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.